These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 12392732)

  • 21. Growth hormone (GH) and insulin-like growth factor I responses after treatments with an orally active GH secretagogue L-163,255 in swine.
    Chang CH; Rickes EL; McGuire L; Frazier E; Chen H; Barakat K; Nargund R; Patchett A; Smith RG; Hickey GJ
    Endocrinology; 1996 Nov; 137(11):4851-6. PubMed ID: 8895356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles.
    Jacks T; Smith R; Judith F; Schleim K; Frazier E; Chen H; Krupa D; Hora D; Nargund R; Patchett A; Hickey G
    Endocrinology; 1996 Dec; 137(12):5284-9. PubMed ID: 8940347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abuse of recombinant human growth hormone: studies in two different dog models.
    Rigamonti AE; Scanniffio D; Bonomo SM; Cella SG; Sartorio A; Müller EE
    Neuroendocrinology; 2004; 79(5):237-46. PubMed ID: 15218318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preliminary pharmacokinetics of the new antitussive compound vadocaine hydrochloride in animals.
    Mäntylä R; Männistö PT; Vuorela A; Nissinen E
    Arzneimittelforschung; 1988 Apr; 38(4A):624-7. PubMed ID: 3395399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral bioavailability and pharmacokinetics of DRF-4367, a new COX-2 inhibitor in rats.
    Ramesh M; Mamidi RN; Jagannath K; Singh SK; Rao KS; Rao YK; Seshagirirao C; Rajagopalan R; Srinivas NR
    Eur J Drug Metab Pharmacokinet; 2003; 28(2):137-41. PubMed ID: 12877572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 2: Discovery of potent, selective, and orally bioavailable compounds.
    Shen DM; Shu M; Willoughby CA; Shah S; Lynch CL; Hale JJ; Mills SG; Chapman KT; Malkowitz L; Springer MS; Gould SL; DeMartino JA; Siciliano SJ; Lyons K; Pivnichny JV; Kwei GY; Carella A; Carver G; Holmes K; Schleif WA; Danzeisen R; Hazuda D; Kessler J; Lineberger J; Miller MD; Emini EA
    Bioorg Med Chem Lett; 2004 Feb; 14(4):941-5. PubMed ID: 15012998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disposition of the opioid antagonist, LY255582, in rats and dogs.
    Swanson SP; Catlow J; Pohland RC; Chay SH; Johnson T
    Drug Metab Dispos; 1995 Sep; 23(9):916-21. PubMed ID: 8565781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.
    Ghigo E; Gianotti L; Arvat E; Ramunni J; Valetto MR; Broglio F; Rolla M; Cavagnini F; Müller EE
    J Clin Endocrinol Metab; 1999 Jan; 84(1):285-90. PubMed ID: 9920097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat.
    van Beijsterveldt LE; Geerts RJ; Leysen JE; Megens AA; Van den Eynde HM; Meuldermans WE; Heykants JJ
    Psychopharmacology (Berl); 1994 Feb; 114(1):53-62. PubMed ID: 7531352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats.
    Lee J; Kwon A; Chae HW; Lee WJ; Kim TH; Kim HS
    Yonsei Med J; 2018 Dec; 59(10):1174-1180. PubMed ID: 30450851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced Pulsatile Growth Hormone Secretion and Altered Metabolic Hormones by in Vivo Hexarelin Treatment in Streptozotocin-Induced Diabetic Rats.
    Zhang X; Yang JK; Chen C
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30297647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endocrine and orexigenic actions of growth hormone secretagogues in rainbow trout (Oncorhynchus mykiss).
    Shepherd BS; Johnson JK; Silverstein JT; Parhar IS; Vijayan MM; McGuire A; Weber GM
    Comp Biochem Physiol A Mol Integr Physiol; 2007 Mar; 146(3):390-9. PubMed ID: 17240179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Absorption, distribution, metabolism and excretion of [14C]ebastine after a single administration in rats.
    Fujii T; Matsumoto S; Amejima H; Hatoyama T; Nakao M; Kagemoto A; Tanaka K; Miyazaki H
    Arzneimittelforschung; 1994 Apr; 44(4):527-38. PubMed ID: 7912071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of acute and repeated intravenous administration of L-692,585, a novel non-peptidyl growth hormone secretagogue, on plasma growth hormone, IGF-1, ACTH, cortisol, prolactin, insulin, and thyroxine levels in beagles.
    Jacks T; Hickey G; Judith F; Taylor J; Chen H; Krupa D; Feeney W; Schoen W; Ok D; Fisher M
    J Endocrinol; 1994 Nov; 143(2):399-406. PubMed ID: 7830002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs.
    Weckbecker G; Briner U; Lewis I; Bruns C
    Endocrinology; 2002 Oct; 143(10):4123-30. PubMed ID: 12239124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 3: SAR studies on the benzylpyrazole segment.
    Shu M; Loebach JL; Parker KA; Mills SG; Chapman KT; Shen DM; Malkowitz L; Springer MS; Gould SL; DeMartino JA; Siciliano SJ; Salvo JD; Lyons K; Pivnichny JV; Kwei GY; Carella A; Carver G; Holmes K; Schleif WA; Danzeisen R; Hazuda D; Kessler J; Lineberger J; Miller MD; Emini EA
    Bioorg Med Chem Lett; 2004 Feb; 14(4):947-52. PubMed ID: 15012999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose and species dependent pharmacokinetics of a novel sigma receptor antagonist, DuP 734.
    Kapil RP; Lam GN
    Res Commun Mol Pathol Pharmacol; 1995 Apr; 88(1):3-20. PubMed ID: 7620836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insulin-like growth factor-I down-regulates ghrelin receptor (growth hormone secretagogue receptor) expression in the rat pituitary.
    Kamegai J; Tamura H; Shimizu T; Ishii S; Sugihara H; Oikawa S
    Regul Pept; 2005 Apr; 127(1-3):203-6. PubMed ID: 15680488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Growth hormone (GH)-releasing hormone (GHRH) and the GH secretagogue (GHS), L692,585, differentially modulate rat pituitary GHS receptor and GHRH receptor messenger ribonucleic acid levels.
    Kineman RD; Kamegai J; Frohman LA
    Endocrinology; 1999 Aug; 140(8):3581-6. PubMed ID: 10433214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolism, pharmacokinetics, tissue distribution, and excretion of [14C]CP-424391 in rats.
    Khojasteh-Bakht SC; O'donnell JP; Fouda HG; Potchoiba MJ
    Drug Metab Dispos; 2005 Jan; 33(1):190-9. PubMed ID: 15486077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.